Zymeworks (ZYME) Set to Announce Earnings on Thursday

Zymeworks (NYSE:ZYME) will announce its earnings results after the market closes on Thursday, October 31st. Analysts expect the company to announce earnings of ($0.40) per share for the quarter. Individual interested in listening to the company’s earnings conference call can do so using this link.

Zymeworks (NYSE:ZYME) last released its quarterly earnings results on Thursday, August 1st. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.01. Zymeworks had a negative return on equity of 21.97% and a negative net margin of 179.42%. The business had revenue of $19.24 million during the quarter, compared to the consensus estimate of $23.16 million. During the same period in the previous year, the company posted ($0.76) EPS. On average, analysts expect Zymeworks to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Zymeworks Stock Down 0.2 %

Shares of NYSE:ZYME opened at $13.11 on Thursday. The stock has a market capitalization of $926.94 million, a PE ratio of -7.32 and a beta of 1.20. The firm’s 50 day moving average price is $12.23 and its 200-day moving average price is $10.26. Zymeworks has a twelve month low of $6.51 and a twelve month high of $14.05.

Analyst Upgrades and Downgrades

ZYME has been the topic of several recent research reports. Stifel Nicolaus increased their price target on shares of Zymeworks from $20.00 to $21.00 and gave the stock a “buy” rating in a research report on Friday, August 2nd. HC Wainwright reaffirmed a “neutral” rating and issued a $12.00 target price on shares of Zymeworks in a report on Tuesday.

Zymeworks Company Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.